Stuttgart, 17 June 2021 (dpa/MIA) – German pharmaceutical company CureVac has suffered a serious setback in the development of its coronavirus vaccine.
Its vaccine candidate CVnCoV achieved a preliminary efficacy of only 47 per cent against Covid-19 disease “of any severity,” the Tuebingen-based company announced late Wednesday in a mandatory release.
The potential jab therefore did not meet the specified statistical criteria for success according to the interim analysis, the company said.
The CureVac candidate has been in the final 2b/3 phase of trials for some time and results at this stage are key for a potential approval for use.
The company’s stock price plunged by more than half in after-hours US trading on Wednesday.
CureVac had long been considered a key candidate in the international race for approval of coronavirus vaccines.
But while numerous competitors have vaccines that have been administered worldwide for months, CureVac is still collecting data.
Up to the beginning of June, the company said it expected an approval in the European Union at least for the second quarter, depending on the clinical trial data.
But it was then announced the process would be delayed further.
CureVac chief executive Franz-Werner Haas said the company had hoped for stronger results in the interim analysis.
However, he said, the ongoing trial will continue until the final analysis.
“The final efficacy could still change,” he said.